ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  04:00 2022-06-29 pm EDT
11.68 USD   +1.74%
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Allogene Therapeutics : ALLO May 2022 Corporate Presentation

05/27/2022 | 03:11am EDT

The Next Revolution in Cell Therapy

Leading Today, Defining Tomorrow

May 2022

Legal Disclaimers

To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: the timing and ability to progress the ALPHA2, UNIVERSAL, IGNITE and TRAVERSE trials, including advancing to the Phase 2 portion of the ALPHA2 trial; the timing and ability to initiate the EXPAND trial for ALLO-647; clinical outcomes, which may materially change as more patient data become available; the ability to manufacture AlloCAR T™ products, including obtaining FDA agreement to use ALLO-501A manufactured at the Company's manufacturing facility for use in the ALPHA2 trial; the projection related to the number of AlloCAR T doses that can be produced at Cell Forge 1 at scale on an annual basis; the potential benefits of AlloCAR T. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended March 31, 2022.

Caution should be exercised when interpreting results from separate trials involving separate product candidates. There are differences in the clinical trial design, patient populations, follow-up times, and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

2

Allogene: Creating the Allogeneic Cell Therapy Playbook

4 Foundational platform technologies

• AlloCAR TTM

• TurboCARTM

• iPSC

• Allogeneic manufacturing

~330

employees

defining the field and writing the

allogeneic CAR T playbook

>

more patients treated

with AlloCAR TTM

product candidates

than any other

145

allogeneic CAR T

Patients

treated

$733

million

in cash, cash equivalents and investments as of Mar 31, 2022

singular focus on allogeneic cell therapy

3

AlloCAR T: Potential to Break the Bottleneck in Cell Therapy

Limited Manufacturing Slots

Access Only in Specialty CAR T Centers

Disease Progression During Waiting Interval

Manufacturing Failures

Bridging Therapy

Higher Cost

Autologous

Single

CAR T

Manufacturing

Run

Personalized Therapy

1 Patient Per Run

Restricted Market Expansion/Growth

Single

AlloCAR T

Manufacturing

Run

Pharmaceutical Product

Consistent Product

Immediate Treatment

Scalable Manufacturing

Potential for Outpatient Use

Administration in the Community Setting

Ability to Meet Patient Demand

100+ of Patients Per Run

Untapped Market Potential

4

CONFIDENTIAL

Cell Forge 1: Fully-OperationalCommercial-Ready Facility

5

CONFIDENTIAL

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Allogene Therapeutics Inc. published this content on 26 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2022 07:07:23 UTC.


© Publicnow 2022
All news about ALLOGENE THERAPEUTICS, INC.
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell Small Cap Comp Growth In..
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2000 Growth Index
CI
06/23INSIDER SELL : Allogene Therapeutics
MT
06/17ALLOGENE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Financi..
AQ
06/13TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..
CI
06/08Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma
DJ
06/08Allogene's Potential Cancer Treatment Gets FDA's Regenerative Medicine Advanced Therapy..
MT
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,12 M - -
Net income 2022 -367 M - -
Net cash 2022 326 M - -
P/E ratio 2022 -4,53x
Yield 2022 -
Capitalization 1 677 M 1 677 M -
EV / Sales 2022 11 115x
EV / Sales 2023 252x
Nbr of Employees 334
Free-Float 55,8%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 11,68 $
Average target price 25,71 $
Spread / Average Target 120%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-21.72%1 649
GILEAD SCIENCES, INC.-13.95%78 031
VERTEX PHARMACEUTICALS27.66%70 632
REGENERON PHARMACEUTICALS, INC.-5.37%64 046
WUXI APPTEC CO., LTD.-14.46%44 352
BIONTECH SE-45.76%33 979